Isomorphic Labs, an AI-first

Isomorphic Labs，一家以人工智能为先的公司

drug design

药物设计

and development company, announced it has raised $600 Million in its first external

和发展公司，宣布已在首次外部融资中筹集了6亿美元

funding

资金

round. The financing round is led by Thrive Capital, with participation from GV, and follow-on capital from existing investor, Alphabet.

轮融资由Thrive Capital领投，GV参与，现有投资者Alphabet也提供了后续资金。

Isomorphic Labs was founded with the ambition to leverage the power of AI to reimagine and accelerate drug discovery to bring much-needed treatments to millions of patients globally. The company aims to apply its pioneering AI drug design engine to deliver biomedical breakthroughs and is advancing drug design programs across multiple therapeutic areas and drug modalities..

Isomorphic Labs 的创立目标是利用人工智能的力量，重新构想和加速药物发现过程，为全球数百万患者带来亟需的治疗方案。该公司旨在应用其开创性的 AI 药物设计引擎来实现生物医学突破，并正在多个治疗领域和药物模式上推进药物设计项目。

“We're excited to bring together a top-tier investor group with deep AI and life sciences expertise as we aim to transform this industry through an interdisciplinary approach,ˮ said Isomorphic Labs founder and CEO, Sir Demis Hassabis. “This funding will further turbocharge the development of our next-generation AI drug design engine, help us advance our own programs into clinical development, and is a significant step forward towards our mission of one day solving all disease with the help of AI.ˮ.

“我们很高兴能够汇集一群具有深厚人工智能和生命科学专业知识的一流投资者，因为我们旨在通过跨学科的方法来改变这个行业，”Isomorphic Labs创始人兼首席执行官Demis Hassabis爵士表示。“这笔资金将进一步加速我们下一代人工智能药物设计引擎的开发，帮助我们将自己的项目推进到临床开发阶段，并且是我们有朝一日借助人工智能解决所有疾病这一使命的重要一步。”

Since its founding, the company has developed a number of next-generation AI models that come together to form its unified AI drug design engine that works across multiple therapeutic areas and drug modalities. One example breakthrough model is AlphaFold 3, developed and released in May 2024 by Isomorphic Labs together with Google DeepMind, with the ability to accurately predict the structure and interactions of all of lifeʼs molecules.

自成立以来，该公司开发了多个下一代人工智能模型，这些模型共同构成了其跨多个治疗领域和药物模式的统一 AI 药物设计引擎。其中一个突破性模型是 AlphaFold 3，由同构实验室与谷歌 DeepMind 在 2024 年 5 月共同开发和发布，该模型能够准确预测所有生命分子的结构和相互作用。

Leveraging these state-of-the-art AI technologies, Isomorphic Labs has established a drug discovery portfolio consisting of partnered programs with pharmaceutical industry leaders Eli Lilly and Novartis, as well as internal programs primarily focused in oncology and immunology. Novartis and Isomorphic Labs recently expanded the scope of their original collaboration just over a year after initiating the relationship..

利用这些最先进的AI技术，Isomorphic Labs已经建立了一个药物发现组合，其中包括与制药业领导者礼来和诺华的合作项目，以及主要集中在肿瘤学和免疫学的内部项目。诺华和Isomorphic Labs在建立合作关系仅一年多后，最近扩大了原有合作的范围。

ˮAt Thrive, we aim to invest in category-defining companies with singular conviction, and that has led us to Isomorphic Labs,' said Joshua Kushner, Founder and CEO of Thrive Capital. 'We believe Isomorphic has earned a rare position to define a new age of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made to date.ˮ.

“在Thrive，我们旨在投资具有独特信念的定义类别的公司，这使得我们选择了同构实验室，”Thrive Capital的创始人兼首席执行官Joshua Kushner说道。“我们相信同构实验室已经获得了定义一个药物发现和设计新时代的罕见地位，他们的使命以及迄今为止取得的非凡进展深深地启发了我们。”

The investment will accelerate Isomorphic Labsʼ frontier AI research and development, to rapidly advance the companyʼs next-generation AI drug design engine. Isomorphic Labs will consequently be expanding its team of world-class talent as part of its next phase of growth.

这项投资将加速Isomorphic Labs的前沿人工智能研发，快速推进公司下一代人工智能药物设计引擎的发展。在此成长的下一阶段，Isomorphic Labs将扩大其世界级人才团队。

'AI and machine learning have long held the promise of transforming drug discovery, yet few companies over the past decade have unlocked their full potential. After witnessing the extraordinary pace of innovation at Isomorphic Labs, we believe their pioneering approach will redefine AI-powered drug discovery,ˮ said Dr.

“人工智能和机器学习长期以来一直有望变革药物发现，但在过去的十年中，很少有公司能够充分释放它们的潜力。在见证了Isomorphic Labs非凡的创新速度后，我们相信他们开创性的方法将重新定义人工智能驱动的药物发现，”博士说道。

Krishna Yeshwant, Managing Partner at GV. “With Sir Demis Hassabis at the helm, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology. We're proud to support them as they advance the development of new treatments for patients.'.

GV管理合伙人克里希纳·耶什万特表示：“在德米斯·哈萨比斯爵士的带领下，Isomorphic汇集了一支在生命科学与技术交叉领域卓越的团队。我们很自豪能支持他们推进患者新疗法的开发。”

https://www.bionity.com/en/news/1185945/next-generation-ai-drug-design-engine.html

https://www.bionity.com/zh/news/1185945/next-generation-ai-drug-design-engine.html

Artificial intelligence predicts the future of artificial intelligence research

人工智能预测人工智能研究的未来

AI algorithm predicts the direction in which your research field is likely to evolve

人工智能算法预测你的研究领域可能演变的方向

Read news

读新闻

Most read news

最受关注的新闻

1

1

Fascinating new findings: Obesity starts in the brain

令人着迷的新发现：肥胖始于大脑

2

2

A method to purify proteins with light

一种用光纯化蛋白质的方法

3

3

Antimalarial drug together with anticancer drug is efficient against leukemia

抗疟疾药物与抗癌药物一起对白血病有效

4

4

Groundbreaking AI tool generates 3D map of the brain

开创性的 AI 工具生成大脑的 3D 地图

5

5

Extreme Mutation Hotspot in Bacteria Discovered: Study Links High Mutation Rates to Transcriptional Activation

细菌中发现极端突变热点：研究将高突变率与转录激活联系起来

Topics

主题

drug design

药物设计

artificial intelligence

人工智能

funding

资金

drug discovery

药物发现

machine learning

机器学习

Show all

显示全部

Show less

显示较少

Organizations

组织机构

Isomorphic Labs

同构实验室